Amendment: SEC Form SC 13G/A filed by Solventum Corporation
$SOLV
Medical/Dental Instruments
Health Care
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 10/1/2025 | $77.00 | Neutral | UBS |
| 9/11/2025 | $80.00 | Hold | Jefferies |
| 7/15/2025 | $103.00 | Equal-Weight → Overweight | Morgan Stanley |
| 7/1/2025 | $90.00 | Hold → Buy | Argus |
| 6/6/2025 | Sector Weight | KeyBanc Capital Markets | |
| 5/19/2025 | $87.00 | Neutral → Overweight | Piper Sandler |
| 12/4/2024 | $70.00 | Neutral | Mizuho |
| 10/8/2024 | $82.00 | Buy | Stifel |
SCHEDULE 13G/A - Solventum Corp (0001964738) (Subject)
10-Q - Solventum Corp (0001964738) (Filer)
8-K - Solventum Corp (0001964738) (Filer)
UBS initiated coverage of Solventum with a rating of Neutral and set a new price target of $77.00
Jefferies initiated coverage of Solventum with a rating of Hold and set a new price target of $80.00
Morgan Stanley upgraded Solventum from Equal-Weight to Overweight and set a new price target of $103.00
4 - Solventum Corp (0001964738) (Issuer)
3 - Solventum Corp (0001964738) (Issuer)
4 - Solventum Corp (0001964738) (Issuer)
Expands MedSurg portfolio into the fast-growing synthetic tissue matrices technology space, a part of the broader regenerative tissue matrices category within acute care settings, a $900 million market segment in the U.S.Accelerates Solventum's business transformation through the acquisition of a strategically aligned asset in a technology adjacencyST. PAUL, Minn., Nov. 20, 2025 /PRNewswire/ -- Solventum (NYSE:SOLV) announced today it has entered into a definitive agreement to acquire Acera Surgical (Acera), a privately held bioscience company focused on developing and commercializing fully engineered materials for regenerative wound care for $725 million in cash plus up to $125 million in c
ST. PAUL, Minn., Nov. 20, 2025 /PRNewswire/ -- Solventum (NYSE:SOLV) announced today its Board of Directors has approved a share repurchase program, which authorizes the Company to purchase up to $1 billion of the Company's outstanding common stock. "Our strong financial performance, operating cash generation, and healthy balance sheet give us the flexibility to invest in opportunities that accelerate sustainable growth, pursue targeted tuck-in M&A—such as today's announced acquisition of Acera Medical to expand our advanced wound care portfolio—and return capital to sharehold
Reported sales increased 0.7%; organic sales increased 2.7%Expects full year organic sales growth to be at the high end of +2.0% to +3.0% rangeIncreases full year adjusted earnings per share outlook to $5.98 to $6.08Announces 4-year 'Transform for the Future' initiativeST. PAUL, Minn., Nov. 6, 2025 /PRNewswire/ -- Solventum (NYSE:SOLV) today reported financial results for the third quarter ended September 30, 2025. Third Quarter 2025 Highlights Sales increased 0.7% to $2.1 billion; up 2.7% on an organic basisGAAP diluted earnings per share of $7.22; adjusted diluted earnings p
Reported sales increased 0.7%; organic sales increased 2.7%Expects full year organic sales growth to be at the high end of +2.0% to +3.0% rangeIncreases full year adjusted earnings per share outlook to $5.98 to $6.08Announces 4-year 'Transform for the Future' initiativeST. PAUL, Minn., Nov. 6, 2025 /PRNewswire/ -- Solventum (NYSE:SOLV) today reported financial results for the third quarter ended September 30, 2025. Third Quarter 2025 Highlights Sales increased 0.7% to $2.1 billion; up 2.7% on an organic basisGAAP diluted earnings per share of $7.22; adjusted diluted earnings p
ST. PAUL, Minn., Oct. 16, 2025 /PRNewswire/ -- Solventum (NYSE:SOLV) will release its third quarter fiscal 2025 financial results on Thursday, Nov. 6, 2025, after the U.S. financial markets close. After the release, Solventum management will host a webcast to discuss the results and its business. Other forward-looking and material information may also be discussed during the webcast. Earnings webcast details: Date: Thursday, Nov. 6, 2025 Time: 3:30 p.m. CST / 4:30 p.m. EST Location: https://investors.solventum.com U.S. dial-in +1 (800) 715-9871 International dial-in: +1 (6
Reported sales increased 3.9%; organic sales increased 2.8%Increases full year organic sales growth outlook to +2.0% to +3.0%Increases full year earnings per share outlook to $5.80 to $5.95ST. PAUL, Minn., Aug. 7, 2025 /PRNewswire/ -- Solventum (NYSE:SOLV) today reported financial results for the second quarter ended June 30, 2025. Second Quarter 2025 Highlights Sales increased 3.9% to $2.2 billion; up 2.8% on an organic basisGAAP diluted earnings per share of $0.51; adjusted diluted earnings per share of $1.69Operating cash flow of $169 million; free cash flow of $59 million"
ST. PAUL, Minn., Oct. 21, 2025 /PRNewswire/ -- Solventum (NYSE:SOLV) announced today the appointment of Heather Knight as Chief Commercial Officer, effective November 10, 2025. In this newly created role, Ms. Knight will oversee global commercial and R&D operations across Solventum's MedSurg, Dental Solutions and Health Information Systems segments, and will report directly to CEO Bryan Hanson. Ms. Knight brings over 30 years of leadership experience in the MedTech industry. Most recently, she served as Chief Operating Officer at Baxter International, where she led global sale
BOSTON, Feb. 11, 2025 (GLOBE NEWSWIRE) -- Ampersand Biomedicines, a multi-product platform company developing smarter medicines that act specifically at the site of disease and nowhere else, today announced the appointment of Elizabeth Mily to its Board of Directors as Independent Director. A highly respected healthcare and financial industry veteran with more than 30 years of experience, Mily brings extensive expertise in corporate strategy, business development and investment leadership to Ampersand as it advances its Address, Navigate, Determine (AND)™ Platform to develop programmed biologics. "We are thrilled to welcome Elizabeth to Ampersand's Board as we leverage our AND Platform to
Former Bristol Myers Squibb, Goldman Sachs, and Barclays executive brings deep expertise in corporate strategy, partnership development, public and private financial markets, and management as the organization evolves its leadership and investment strategy Appointment signals plans to capitalize on previous success and maximize impact by expanding equity investments and partnerships with venture capital, large biopharma, and key foundations with a proven team leader and dealmaker BOSTON, Jan. 8, 2025 /PRNewswire/ -- The T1D Fund, an impact investment fund with a focus on accelerating life-changing solutions to treat, prevent, and cure type 1 diabetes (T1D), today announced it appointed Eliza
SC 13G/A - Solventum Corp (0001964738) (Subject)
SC 13G/A - Solventum Corp (0001964738) (Subject)